Is Stryker Corporation (SYK) a good stock to buy?

Olyth's institutional analysis of SYK reveals an Altman Z-Score of 4.02 and a Piotroski F-Score of 5/9. These metrics, combined with its 5-year revenue trend ($25.12B most recent), help investors decide if SYK fits their risk profile.

What is the current P/E ratio for SYK?

As of the latest trading session, Stryker Corporation (SYK) has a trailing P/E ratio of 39.16.

Who is the CEO of Stryker Corporation?

The current Chief Executive Officer of Stryker Corporation is Kevin A. Lobo.

What was SYK's revenue for the last 5 years?

According to its latest income statements, Stryker Corporation reported annual revenues of $25.12B (2025), $22.59B (2024), $20.50B (2023), $18.45B (2022), $17.11B (2021) respectively.

Does SYK pay a dividend?

Stryker Corporation currently pays a dividend to its shareholders, with a trailing dividend yield of 1.04%.

How much debt and cash flow does SYK have?

In its latest reporting period, Stryker Corporation generated $4.28B in Free Cash Flow against a total debt load of $14.86B.

What is the Price-to-Book (P/B) ratio of Stryker Corporation?

The Price-to-Book (P/B) ratio for Stryker Corporation (SYK) is currently 5.67.

What is the Price-to-Sales (P/S) ratio of SYK?

Based on trailing twelve-month data, Stryker Corporation (SYK) trades at a Price-to-Sales (P/S) ratio of 5.06.

What is Stryker Corporation's Return on Equity (ROE)?

Stryker Corporation (SYK) has a Return on Equity (ROE) of 15.04%, representing its profitability relative to shareholder equity.

SYK

Stryker Corporation · Healthcare

332.30

0.23%(+0.76)

Prev. Close

335.66

1.01%(+3.36)

Pre-market

Last Updated: — ET

52W L: $319.3252W H: $404.87

$332.30

CHG-22.81 (-6.42%)

H$367.99

L$319.32

VOL38M

SYK (1h)

Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Sector

Healthcare

Industry

Medical - Devices

Employees

53,000

IPO Date

1980-03-17

Beta

0.93

Websitewww.stryker.com↗

SYK

Allspring Global Investments Holdings LLC Has $5.37 Million Stake in Stryker Corporation $SYK

Runnymede Capital Advisors Inc. Takes $3.25 Million Position in Stryker Corporation $SYK

Savvy Advisors Inc. Has $1.98 Million Stake in Stryker Corporation $SYK

Stryker (NYSE:SYK) & IM Cannabis (NASDAQ:IMCC) Critical Analysis

Here's Why Stryker (SYK) is a Strong Growth Stock

Stryker to announce financial results for its first quarter of fiscal year 2026